Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736054 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
A Phase 1 study of Prostate Adenocarcinoma, sponsored by Hoag Memorial Hospital Presbyterian.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06736054 is a Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 8 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06736054, a Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Hoag Memorial Hospital Presbyterian.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utilize Fluorine 18 or Gallium 68 as the positron emitter for PET imaging. However, these isotopes have short half-lives which limit the geographic distribution range of tracers made with these isotopes. Copper 61 (61Cu) has a 3.3 hour half-life, which would allow for far greater distribution range following radiotracer production. This phase I trial will test the safety and effectiveness of a novel MI radiotracer that uses 61Cu as its positron emitting isotope and targets Prostate Specific Membrane Antigen (PSMA) for imaging prostate cancer. A successful trial will provide the ability to advance this novel 61Cu-NODAGA-PSMA radioisotope into phase II trials, as well as open a new paradigm into the production of MI radioisotopes with 61Cu.
Conditions Studied
Interventions
- DRUG Copper 61-PSMA PET/CT
Study Locations (1)
California
- Hoag Memorial Hospital Presbyterian - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06736054
The ClinicalTrials.gov registry entry for NCT06736054 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (96% lower). The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Copper 61-PSMA PET/CT is the first listed.
NCT06736054 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06736054 about?
NCT06736054 is a clinical study titled "A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer". Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utilize Fluorine 18 or Gallium 68 as the positron emitter for PET imaging. However, these isotopes have short half-lives which limit the geographic distribu...
What is the current status of trial NCT06736054?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-10-14. Estimated completion is 2025-03-31.
What conditions does trial NCT06736054 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06736054?
The interventions under investigation include: Copper 61-PSMA PET/CT (DRUG).
Who is sponsoring clinical trial NCT06736054?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736054 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
PSMA PET Response Guided SabR in High Risk Pca
RECRUITING · Phase 1
-
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
RECRUITING · Phase 1
-
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
RECRUITING · Phase 1
-
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.